Under construction – not a live service
Sign in
Active, not recruitingNo phase

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

Key facts

Who runs it
CereVasc Inc
Where
Boston, Buffalo, Jacksonville, Kansas City, Lexington, New Haven, New York, Providence, Richmond, Rochester, and The Bronx, United StatesSee the 11 sites
Trial code
Status
Active, not recruiting
People taking part
50 people, planned
Started
20 Apr 2022
Expected to end
30 Jun 2030
Type of study
Interventional
Treatments tested
  • eShunt Implant
Record updated
19 June 2025

Who can take part

Age
65 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Patients 65-85 years old for whom traditional CSF shunt placement is indicated based upon a diagnostic normal pressure hydrocephalus (NPH) evaluation
  • Patient or legally authorized representative is able and willing to provide written informed consent
  • History or evidence of gait impairment duration ≥6 months
  • Clinical presentation consistent with NPH including 2 or more of the clinical triad (i.e., history of gait disturbance, progressive mental deterioration, and urinary urgency or incontinence), together with:; Brain MRI signs of ventricular enlargement disproportionate to cerebral atrophy (Evans' Index >0.3) and the absence of severe hippocampal atrophy; Pre-procedure spinal tap test or lumbar drain with subsequent gait disturbance improvement (Timed Up and Go Test) of at least 20%; CSF opening pressure ≥8 cmH2O; Baseline cognitive evaluation assessed by Montreal Cognitive Assessment (MoCA) test score ≥12
  • Pre-procedure MRI confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by subject screening committee (SSC)
  • Pre-procedure CT confirmation of anatomy suitable for eShunt Procedure, as described in Section 1.8.3.4.2 and confirmed by SSC

Who cannot take part

  • Prior or existing shunts, endoscopic third ventriculostomy, or any previous surgical intervention for hydrocephalus
  • Currently participating in another investigational drug or device trial that could conflict with study data collection or follow-up
  • Active systemic infection or infection detected in CSF
  • Hypersensitivity or contraindication to heparin or radiographic contrast agents which cannot be adequately pre-medicated, desensitized or where no alternative is available
  • Atrial septal defect or patent foramen ovale identified on cardiac echocardiogram
  • History of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency
  • Stroke or transient ischemic attack within 180 days of eShunt Procedure
  • Presence of a deep vein thrombosis superior to the popliteal vein
  • Other medical illnesses that may cause the patient to be non-compliant with the protocol or confound data interpretation
  • International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) results outside of normal range (INR 0.8-1.4; PTT 25-35 seconds)
  • Unable to walk 10 meters (33 feet) with or without an assistive device
  • Signs or symptoms of obstructive hydrocephalus
  • Occlusion or stenosis of the internal jugular vein
  • Venous distension in the neck on physical exam
  • Presence of a posterior fossa tumor or mass
  • Life expectancy < 1 year
  • Unwilling or unable to comply with follow-up requirements

Where in United States

  • Beth Israel Deaconess Medical CenterBoston, United StatesNo longer taking part
  • University at BuffaloBuffalo, United StatesNo longer taking part
  • Baptist HealthJacksonville, United StatesNo longer taking part
  • University of Kansas Medical CenterKansas City, United StatesNo longer taking part
  • University of Kentucky Research FoundationLexington, United StatesNo longer taking part
  • Yale UniversityNew Haven, United StatesNo longer taking part
  • NYU Langone HealthNew York, United StatesNo longer taking part
  • Rhode Island HospitalProvidence, United StatesNo longer taking part
  • Virginia Commonwealth UniversityRichmond, United StatesNo longer taking part
  • University of Rochester Medical CenterRochester, United StatesNo longer taking part
  • Montefiore Medical CenterThe Bronx, United StatesNo longer taking part

About the trial

What the trial wants to find out

The eShunt® System is a minimally invasive method of treating communicating hydrocephalus. The eShunt System includes a proprietary eShunt Delivery System and the eShunt Implant, a permanent implant deployed in a minimally invasive, neuro-interventional procedure. The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.

The group in the trial

  • Treatment ArmTreatment being tested

    The Treatment Arm receives the eShunt Implant.

    Treatment: eShunt Implant

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
US Pilot Study to Evaluate the Safety and Effectiveness of the CereVasc® eShunt® System in the Treatment of Normal Pressure Hydrocephalus
Publications
Record updated
19 June 2025